Jazz Pharmaceuticals, Inc.
 (JAZZ)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 10, 2015, 9:13 AM
    | Nov. 10, 2015, 9:13 AM | 12 Comments
  • Nov. 9, 2015, 4:08 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 EPS of $2.52 misses by $0.04.
    • Revenue of $340.9M (+11.2% Y/Y) misses by $7.25M.
    • Shares -6.4%.
    | Nov. 9, 2015, 4:08 PM
  • Nov. 8, 2015, 5:35 PM
  • Oct. 16, 2015, 12:32 PM
    • Opko Health (OPK +2.5%) initiated with Overweight rating and $14 (47% upside) price target by JP Morgan.
    • Jazz Pharmaceuticals (JAZZ +1.7%) initiated with Outperform rating and $200 (44% upside) price target by Northland Capital Markets.
    • Mallinckrodt (MNK) initiated with Outperform rating and $92 (37% upside) price target by Northland Capital Markets.
    • Shire (SHPG +1.1%) initiated with Outperform rating and $288 (38% upside) price target by Northland Capital Markets.
    • Nabriva Therapeutics (NBRV +2.2%) initiated with Outperform rating and $19 (90% upside) price target by Leerink.
    • Penumbra (PEN -0.2%) initiated with Buy rating and $48 (20% upside) price target by Canaccord Genuity.
    • REGENXBIO (RGNX -3.6%) initiated with Overweight rating and $36 (100% upside) price target by Piper Jaffray.
    • Dyax (DYAX -0.9%) upgraded to Outperform from Market Perform by Leerink. Price target raised to $36 (29% upside) from $25.
    • Eli Lilly (LLY +1.5%) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $105 (30% upside) from $89.
    • Athenahealth (ATHN -4.6%) downgraded to Underperform from Buy by Jefferies. Price target lowered to $105 (22% downside risk) from $125.
    • Halyard Health (HYH -1.5%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $27 (6% downside risk) from 38.
    | Oct. 16, 2015, 12:32 PM | 13 Comments
  • Sep. 30, 2015, 9:34 AM
    • The FDA accepts under Priority Review Jazz Pharmaceuticals' (NASDAQ:JAZZ) New Drug Application (NDA) seeking clearance of Orphan Drug- and Fast Track-tagged defibrotide for the treatment of hepatic veno-occlusive disease (VOD), with evidence of multi-organ dysfunction following hematopoietic stem cell transplantation (HSCT). The PDUFA date is March 31, 2016.
    • HSCT is a potential cure for certain blood cancers/disorders. Hepatic VOD is a rare, early and life-threatening complication of HSCT. The mortality rate is greater than 80%.
    • Defibrotide is an anticoagulant with multiple modes of action.
    • Priority Review shortens the review clock to six months from the usual ten.
    | Sep. 30, 2015, 9:34 AM
  • Aug. 5, 2015, 4:07 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 EPS of $2.41 in-line.
    • Revenue of $333.75M (+14.6% Y/Y) misses by $2.11M.
    | Aug. 5, 2015, 4:07 PM
  • Jun. 24, 2015, 1:43 PM
    • Screen criteria: market cap >=$1B; average daily turnover >=400K shares; % change in mutual fund ownership (most recent qtr) >=0%; PEG ratio: <=1.0.
    • (EVHC -0.8%)(ESRX -0.3%)(GILD -0.2%)(JAZZ -1.3%)(KANG -1.5%)(MOH -0.4%)(MYL -0.3%)(SHPG -1%)(UTHR -3.6%)(VRX -1.4%)(ZTS -1.2%)
    • This is not a list of Buy/Sell recommendations, but rather a targeted list of stocks that may be suitable for more in-depth research.
    | Jun. 24, 2015, 1:43 PM | 13 Comments
  • May 8, 2015, 7:55 AM
    • Jazz Pharmaceuticals (JAZZ +1.2%) Q1 results: Revenues: $309.3M (+25.3%); COGS: $28.3M (-8.4%); R&D Expense: $27.2M (+50.3%); SG&A: $112.4M (+5.6%); Operating Income: $116.8M (+275.1%); Net Income: $70.7M (+176.3%); EPS: $1.12 (+170.9%); Quick Assets: $782.6M (+14.4%).
    • 2015 Guidance: Revenues: $1.31B - 1.37B; Net Product Sales: $1.303B - 1.363B; Xyrem: $950M - 970M; Erwinaze/Erwinase: $200M - 215M; Defitelio/defibrotide: $73M - 83M; EPS: $5.17 - 5.70; Non-GAAP EPS: $9.45 - 9.75.
    | May 8, 2015, 7:55 AM
  • May 7, 2015, 4:16 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q1 EPS of $1.99 misses by $0.15.
    • Revenue of $309.3M (+25.3% Y/Y) beats by $0.38M.
    • Shares -1.42%.
    | May 7, 2015, 4:16 PM
  • May 7, 2015, 3:37 PM
    • Jazz Pharmaceuticals (JAZZ +1%) reports Q1 results after the close today. Consensus view is EPS of $2.14 on revenues of $309M.
    | May 7, 2015, 3:37 PM
  • Mar. 30, 2015, 1:03 PM
    • According to Bloomberg, privately-held Rome-based drug firm Sigma-Tau Group is attracting interest from prospective bidders for its rare diseases business. The unit, valued as high as $1B, could be nice fit with Jazz Pharmaceuticals (JAZZ -0.3%) or Shire plc (SHPG -1%). Last year, Jazz acquired the rights to Sigma-Tau's defibrotide in the Americas for as much as $250M. No formal negotiations are underway, though, and the Cavazza family that owns the business may choose not to sell.
    • Sigma-Tau, founded in 1957, generated sales of €697M ($757M) in 2013, with the rare diseases unit contributing €165M. The 220-employee unit focuses on blood diseases and cancer.
    • Previously: Jazz kicks off Fast Track review process for VOD med (Dec. 12, 2014)
    • Previously: Jazz secures rights to defibrotide in the Americas (July 2, 2014)
    | Mar. 30, 2015, 1:03 PM
  • Feb. 24, 2015, 4:39 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) Q4 results ($M): Total Revenues: 328.1 (+39.1%); Product Sales: 324.2 (+38.7%); Operating Expenses: 169.4 (+46.4%); Operating Income: 129.9 (+37.5%); Net Income: 81.6 (+47.6%); EPS: 1.30 (+44.4%); Quick Assets: 684.0 (+7.5%).
    • Key product sales: Xyrem: 222.5 (+35.5%); Erwinaze/Erwinase: 52.8 (+21.4%); Defitelio/defibrotide: 19.2; Prialt: 10.0 (+56.3%).
    • 2015 Guidance: Revenues: $1.31B - 1.37B; Net Product Sales: $1.303B - 1.363B; Xyrem: $950M - 970M; Erwinaze/Erwinase: $200M - 215M; Defitelio/defibrotide: $73M - 83M; EPS: $5.17 - 5.70; Non-GAAP EPS: $9.45 - 9.75.
    | Feb. 24, 2015, 4:39 PM
  • Feb. 24, 2015, 4:17 PM
    • Jazz Pharmaceuticals (NASDAQ:JAZZ): Q4 EPS of $2.44 beats by $0.14.
    • Revenue of $328.14M (+39.2% Y/Y) beats by $9.02M.
    • Shares -1.2%.
    | Feb. 24, 2015, 4:17 PM
  • Feb. 23, 2015, 5:35 PM
  • Feb. 9, 2015, 12:21 PM
    • The following are healthcare companies whose after-tax margins have expanded the past three quarters and trade at least 500K shares per day:
    • (ACOR -0.7%)(BCR -1.5%)(BIIB -0.2%)(CAH -1.2%)(CPHD +1.3%)(EVHC -1.6%)(ILMN +0.7%)(JAZZ -1.7%)(LCI +7.3%)(MNK -0.5%)(SHPG -2.9%)(SYK -0.2%)(TMO -0.7%)(UTHR +1.4%)(VRX).
    • This is not a list of "Buy" recommendations, but rather a targeted list of firms that may be suitable for more in-depth research.
    | Feb. 9, 2015, 12:21 PM | 3 Comments
  • Jan. 14, 2015, 11:51 AM
    • Flamel Technologies (FLML -25%) drops on a 6x surge in volume in apparent response a favorable ruling from the USPTO for Jazz Pharmaceuticals (JAZZ +3.1%) and against the petitions from Par Pharmaceuticals, Roxane Labs and Amneal Pharmaceuticals. The decision reaffirmed the validity of four patents related to Xyrem (#'s 7,895,059, 8,457,988, 7,668,730, 8,589,182).
    • In October, Canaccord Genuity analyst John Newman published a research report reiterating his Buy recommendation on Jazz Pharmaceuticals (JAZZ +3.8%) with a $163 price target based on his view that Flamel's NDA for its once-daily version of Xyrem (sodium oxybate), to be filed under the 505(NYSE:B)(2) paragraph IV pathway, will reference Jazz's orange book-listed patents. This will trigger a lawsuit and and an automatic 30-month stay of approval.
    • The delay will give Jazz more time to develop its once-daily version, JZP-386, which should enter Phase 2 this year.
    | Jan. 14, 2015, 11:51 AM | 11 Comments
Company Description
Jazz Pharmaceuticals PLC is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.
Sector: Healthcare
Industry: Biotechnology
Country: United States